Vanguard Group Inc Avenue Therapeutics, Inc. Transaction History

Vanguard Group Inc

  • $5.46 Trillion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$0.24 - $756.0 $31,576 - $99.5 Million
-131,569 Closed
0 $0
Q2 2022

Aug 12, 2022
SELL
$0.22 - $0.56 $70,638 - $179,807
-321,084 Reduced 70.93%
131,569 $36,000
Q3 2021

Nov 12, 2021
BUY
$1.48 - $2.65 $3,953 - $7,078
2,671 Added 0.59%
452,653 $675,000
Q2 2021

Aug 13, 2021
BUY
$2.41 - $7.11 $1.08 Million - $3.2 Million
449,982 New
449,982 $1.13 Million

About AVENUE THERAPEUTICS, INC.

ATXI Quotes by TradingView
  • Ticker ATXI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,127,720
  • Market Cap $8.13M
  • Description
  • Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...
More about ATXI
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email